These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 19453351)
1. Key opinion leaders: where they come from and how that affects the drugs you prescribe. Meffert JJ Dermatol Ther; 2009; 22(3):262-8. PubMed ID: 19453351 [TBL] [Abstract][Full Text] [Related]
2. Off-label use in dermatology in Germany: what has changed since 2004. Brockmeyer NH; Brucklacher U; Potthoff A; Reich-Schupke S J Dtsch Dermatol Ges; 2009 Nov; 7(11):938-45. PubMed ID: 19386019 [TBL] [Abstract][Full Text] [Related]
3. Off-label uses of biologic agents in dermatology: a 2006 update. Kerns MJ; Graves JE; Smith DI; Heffernan MP Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843 [TBL] [Abstract][Full Text] [Related]
5. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice. Charlton BG Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461 [TBL] [Abstract][Full Text] [Related]
6. Drugs and other product choices. Hyman PM; Carvajal R Dermatol Ther; 2009; 22(3):216-24. PubMed ID: 19453345 [TBL] [Abstract][Full Text] [Related]
7. The rise of the generic drug market and its implications for dermatology. Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148 [TBL] [Abstract][Full Text] [Related]
8. Key opinion leaders: used as a marketing tool by drug companies. Prescrire Int; 2012 Jun; 21(128):163-5. PubMed ID: 22822596 [TBL] [Abstract][Full Text] [Related]
9. The influence of the pharmaceutical industry in medicine. Jelinek GA; Neate SL J Law Med; 2009 Oct; 17(2):216-23. PubMed ID: 19998591 [TBL] [Abstract][Full Text] [Related]
10. Drug therapy in pediatrics: a developing field. Mathis L; Rodriguez W Dermatol Ther; 2009; 22(3):257-61. PubMed ID: 19453350 [TBL] [Abstract][Full Text] [Related]
11. Bias shown in study of better care for patients with skin disease? Ober V; Meires J Fam Med; 2001 Feb; 33(2):82-3. PubMed ID: 11271743 [No Abstract] [Full Text] [Related]
12. Long-term safety of biologics in dermatology. Lima XT; Seidler EM; Lima HC; Kimball AB Dermatol Ther; 2009; 22(1):2-21. PubMed ID: 19222513 [TBL] [Abstract][Full Text] [Related]
13. Differing patterns of methotrexate use for psoriatic disease among dermatologists and rheumatologists. Dupuis EC; Bhole VM; Dutz JP Br J Dermatol; 2012 Aug; 167(2):448-50. PubMed ID: 22309601 [No Abstract] [Full Text] [Related]
15. Drug samples in dermatology: special considerations and recommendations for the future. Alikhan A; Sockolov M; Brodell RT; Feldman SR J Am Acad Dermatol; 2010 Jun; 62(6):1053-61. PubMed ID: 20172623 [TBL] [Abstract][Full Text] [Related]
17. The use of cyclosporine in dermatology: part I. Amor KT; Ryan C; Menter A J Am Acad Dermatol; 2010 Dec; 63(6):925-46; quiz 947-8. PubMed ID: 21093659 [TBL] [Abstract][Full Text] [Related]
18. The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care. Altman DJ Dermatol Clin; 2000 Apr; 18(2):287-96. PubMed ID: 10791155 [TBL] [Abstract][Full Text] [Related]